Martin Reid - Balchem Senior Officer
| BCPC Stock | USD 180.52 0.21 0.12% |
Executive
Martin Reid is Senior Officer of Balchem
| Age | 56 |
| Address | 5 Paragon Drive, Montvale, NJ, United States, 07645 |
| Phone | 845 326 5600 |
| Web | https://www.balchem.com |
Balchem Management Efficiency
The company has return on total asset (ROA) of 0.0642 % which means that it generated a profit of $0.0642 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1104 %, meaning that it created $0.1104 on every $100 dollars invested by stockholders. Balchem's management efficiency ratios could be used to measure how well Balchem manages its routine affairs as well as how well it operates its assets and liabilities. At present, Balchem's Return On Assets are projected to slightly decrease based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.17, whereas Return On Tangible Assets are forecasted to decline to 0.12. At present, Balchem's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 15.7 M, whereas Net Tangible Assets are forecasted to decline to about 129 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chun Lyu | Eshallgo Class A | 40 | |
| Jennifer JD | Merck Company | 46 | |
| MSc MS | Gold Fields Ltd | 63 | |
| Christy Robertson | FormFactor | N/A | |
| Gideon Blumenthal | Merck Company | N/A | |
| Angi Larson | Amtech Systems | N/A | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| Betty Larson | Merck Company | 48 | |
| Gerrit Lotz | Gold Fields Ltd | N/A | |
| Peter Dannenbaum | Merck Company | N/A | |
| Wade Jenke | Amtech Systems | N/A | |
| Ronald Filippo | Madrigal Pharmaceuticals | N/A | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Joerg Koglin | Merck Company | N/A | |
| Dalton III | Merck Company | 57 | |
| PharmD MBA | Madrigal Pharmaceuticals | N/A | |
| Chirfi Guindo | Merck Company | 58 | |
| Shai Shahar | FormFactor | 52 | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| Carole Huntsman | Madrigal Pharmaceuticals | 59 | |
Management Performance
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0642 |
Balchem Leadership Team
Elected by the shareholders, the Balchem's board of directors comprises two types of representatives: Balchem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Balchem. The board's role is to monitor Balchem's management team and ensure that shareholders' interests are well served. Balchem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Balchem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frederic Boned, Senior Health | ||
| CPA CPA, Chief Officer | ||
| Brent Tignor, Senior Officer | ||
| Hatsuki Miyata, General VP | ||
| William CPA, VP Officer | ||
| Carl Bengtsson, CFO Treasurer | ||
| Michael Sestrick, Senior CTO | ||
| Job Gunsteren, Senior Products | ||
| Theodore Harris, CEO and President and Director | ||
| Mark Stach, General Counsel, Secretary | ||
| Hatsuki JD, General VP | ||
| Jonathan Griffin, Senior Development | ||
| Martin Reid, Senior Officer |
Balchem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Balchem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0642 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 6.03 B | ||||
| Shares Outstanding | 32.51 M | ||||
| Shares Owned By Insiders | 0.46 % | ||||
| Shares Owned By Institutions | 90.82 % | ||||
| Number Of Shares Shorted | 442.21 K | ||||
| Price To Earning | 42.37 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Balchem offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Balchem's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Balchem Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Balchem Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Balchem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Balchem Stock refer to our How to Trade Balchem Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Balchem. If investors know Balchem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Balchem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.144 | Dividend Share 0.79 | Earnings Share 3.73 | Revenue Per Share 29.208 | Quarterly Revenue Growth 0.043 |
The market value of Balchem is measured differently than its book value, which is the value of Balchem that is recorded on the company's balance sheet. Investors also form their own opinion of Balchem's value that differs from its market value or its book value, called intrinsic value, which is Balchem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Balchem's market value can be influenced by many factors that don't directly affect Balchem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Balchem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Balchem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Balchem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.